The neoantigen landscape is expanding beyond somatic mutations to include noncoding-derived peptides identified via immunopeptidomics, while new AI frameworks like TrambaHLApan integrate Transformer and Mamba architectures to better predict both antigen presentation and immunogenicity.PubMedPubMed
These methodological advances are critical for improving the clinical utility of personalized mRNA vaccines and TCR-based therapies.PubMed
Advances in HLA ligandome analyses are revealing immunogenic peptides from noncoding regions, expanding the neoantigen pool beyond traditional whole-exome sequencing. This shift is crucial for identifying clinically actionable targets for cancer vaccines and adoptive cell therapies in patients who do not respond to immune checkpoint inhibitors.
mRNA platforms are becoming central to neoantigen vaccine development due to their ability to rapidly encode multiple patient-specific epitopes. The field is moving toward clinically meaningful timelines by integrating tumor-normal sequencing, transcriptomic filtering, and algorithmic prioritization, with specific focus on improving less accurate HLA class II predictions.
Research is focusing on how individualized neoantigen therapies can help a patient's immune system target their cancer in a personalized way.
Relevant work from earlier we're still surfacing — not today's news.